Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in AbbVie Inc. or Teva Pharmaceutical Industries Limited because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how AbbVie Inc. and Teva Pharmaceutical Industries Limited compare based on key financial metrics to determine which better meets your investment needs.

About AbbVie Inc. and Teva Pharmaceutical Industries Limited

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin’s lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Latest Biotechnology and AbbVie Inc., Teva Pharmaceutical Industries Limited Stock News

As of July 31, 2026, AbbVie Inc. had a $443.4 billion market capitalization, compared to the Biotechnology median of $252.6 million. AbbVie Inc.’s stock is up 9.8% in 2026, down 3.2% in the previous five trading days and up 32.56% in the past year.

Currently, AbbVie Inc.’s price-earnings ratio is 123.6. AbbVie Inc.’s trailing 12-month revenue is $62.8 billion with a 9.8% net profit margin. Year-over-year quarterly sales growth most recently was 12.4%. Analysts expect adjusted earnings to reach $14.110 per share for the current fiscal year. AbbVie Inc. currently has a 2.8% dividend yield.

As of July 31, 2026, Teva Pharmaceutical Industries Limited had a $40.8 billion market cap, putting it in the 92nd percentile of all stocks. Teva Pharmaceutical Industries Limited’s stock is up 12.2% in 2026, up 13.6% in the previous five trading days and up 108.02% in the past year.

Currently, Teva Pharmaceutical Industries Limited’s price-earnings ratio is 58.2. Teva Pharmaceutical Industries Limited’s trailing 12-month revenue is $17.3 billion with a 4.1% net profit margin. Year-over-year quarterly sales growth most recently was -0.8%. Analysts expect adjusted earnings to reach $2.143 per share for the current fiscal year. Teva Pharmaceutical Industries Limited does not currently pay a dividend.

How We Compare AbbVie Inc. and Teva Pharmaceutical Industries Limited Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at AbbVie Inc. and Teva Pharmaceutical Industries Limited’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

AbbVie Inc. and Teva Pharmaceutical Industries Limited Stock Value Grades

Company	Ticker	Value
AbbVie Inc.	ABBV	F
Teva Pharmaceutical Industries Limited	TEVA	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

AbbVie Inc. has a Value Score of 17, which is Ultra Expensive. Teva Pharmaceutical Industries Limited has a Value Score of 25, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither AbbVie Inc. or Teva Pharmaceutical Industries Limited has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if AbbVie Inc. or Teva Pharmaceutical Industries Limited is the better investment when it comes to value.

AbbVie Inc. and Teva Pharmaceutical Industries Limited Growth Grades

Company	Ticker	Growth
AbbVie Inc.	ABBV	A
Teva Pharmaceutical Industries Limited	TEVA	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

AbbVie Inc. has a Growth Score of 95, which is Very Strong. Teva Pharmaceutical Industries Limited has a Growth Score of 36, which is Weak.

The Growth Grade Winner: AbbVie Inc.

As you can clearly see from the Growth Grade breakdown above, AbbVie Inc. has a more attractive growth grade than Teva Pharmaceutical Industries Limited. For investors who focus solely on how a company is growing relative to other companies in the same industry, AbbVie Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

AbbVie Inc. and Teva Pharmaceutical Industries Limited’s Momentum Grades

Company	Ticker	Momentum
AbbVie Inc.	ABBV	B
Teva Pharmaceutical Industries Limited	TEVA	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

AbbVie Inc. has a Momentum Score of 74, which is Strong. Teva Pharmaceutical Industries Limited has a Momentum Score of 89, which is Very Strong.

The Momentum Grade Winner: Teva Pharmaceutical Industries Limited

As you can clearly see from the Momentum Grade breakdown above, Teva Pharmaceutical Industries Limited is considered to have stronger momentum compared to AbbVie Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Teva Pharmaceutical Industries Limited could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other AbbVie Inc. and Teva Pharmaceutical Industries Limited Grades

In addition to Value, Momentum and Growth, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether AbbVie Inc. and Teva Pharmaceutical Industries Limited pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, AbbVie Inc. or Teva Pharmaceutical Industries Limited Stock?

Overall, AbbVie Inc. stock has a Value Score of 17, Growth Score of 95 and Momentum Score of 74.

Teva Pharmaceutical Industries Limited stock has a Value Score of 25, Growth Score of 36 and Momentum Score of 89.

Comparing AbbVie Inc. and Teva Pharmaceutical Industries Limited’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.